TinyGemsBreaks Archive - Page 30 of 128

MondayApr 22, 2024 3:31 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Spotlighted in Upcoming Virtual Investor Lunch Break Event

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be featured on the Virtual Investor Lunch Break: The CNSP Opportunity event. During the live video webcast, which is scheduled to begin at 12 p.m. EST, CEO John Climaco will present a corporate overview. He will also discuss the company’s business outlook and opportunity. In addition, the event provides an opportunity for those participating to submit questions; Climaco will answer as many questions as possible I the time provided. A replay of the presentation will…

MondayApr 22, 2024 2:59 pm

TinyGemsBreaks – Diamond Lake Minerals Inc. (DLMI), Evertreen Collaboration Spotlighted in NASDAQ News Today Article

Diamond Lake Minerals (OTC: DLMI), a leading multi-strategy operating company specializing in developing and supporting digital assets and SEC-registered security tokens, has been featured in an article published by NASDAQ News Today. The piece sheds light on Diamond Lake Minerals and Evertreen’s collaboration to continue to combat climate change through joint reforestation efforts, indicating the partnership is a significant step towards a greener and more sustainable future. Since August 2023, DLMI has planted a total of 2500 trees so far, at a rate of 500 per month, with the initiative set to offset 770 tons of CO2. “It has been…

MondayApr 22, 2024 11:26 am

TinyGemsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Enters SID Agreement for Base Resources Transformational Acquisition

Energy Fuels (NYSE American: UUUU) (TSX: EFR), a leading U.S. producer of uranium, rare earth elements (“REEs”) and vanadium has executed a definitive scheme implementation deed (“SID”) with Base Resources Limited. According to the agreement, Energy Fuels has agreed to acquire 100% of the issued shares of Base Resources in consideration for 0.0260 Energy Fuels common shares and A$0.065 in cash; the transaction will be payable by way of a special dividend by Base Resources to its shareholders for each Base Resources ordinary share held. The transaction has a total equity value of an estimated A$375 million. Highlights of the agreement include that…

FridayApr 19, 2024 12:37 pm

TinyGemsBreaks – Diamond Lake Minerals Inc. (DLMI), BOXABL Collaboration Spotlighted in Latest Proactive Interview

Diamond Lake Minerals (OTC: DLMI), a leading multi-strategy operating company specializing in developing and supporting digital assets and SEC-registered security tokens, has been featured in an interview with Proactive. DLMI CEO Brian J. Esposito joined Proactive’s Steve Darling to discuss the company’s long-term real estate vision and its collaboration with BOXABL, Inc., a modular home building company. In the interview, Esposito stated that DLMI’s announcement and partnership with BOXABL mark a pivotal moment in expanding the use cases of BOXABL technology. DLMI and BOXABL, Esposito said, aim to identify, design and develop aesthetically pleasing communities known as Boxable Villages. Esposito…

ThursdayApr 18, 2024 2:30 pm

TinyGemsBreaks – Diamond Lake Minerals Inc. (DLMI), BOXABL Partner to Make ‘Quite the Impact’ in Affordable Housing Market

Diamond Lake Minerals (OTC: DLMI), a forward-thinking multi-strategy operating company specializing in digital assets and SEC-registered security tokens, today announced the beginning of its long-term real estate vision and working relationship with Boxabl, Inc. (“BOXABL”), a revolutionary modular home building company. According to the announcement, the partnership with DLMI “further expands the use cases of BOXABL where together they can identify, design and develop beautiful communities, known as BOXABL Villages.” The announcement further noted that DLMI’s leadership and position on the future of finance through security tokens, combined with all traditional means, will create additional unique opportunities for these villages…

ThursdayApr 18, 2024 1:57 pm

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Welcomes Leading Authority in Alzheimer’s Research to Scientific Advisory Board

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is announcing that Dr. David G. Morgan, PhD, a renowned leader in neurodegenerative disease, has joined its scientific advisory board (“SAB”). The announcement noted that the addition reinforces the company’s commitment to advancing its INM-901 program in the treatment of Alzheimer’s disease. Dr. Morgan is the Director of the Alzheimer’s Alliance and MSU Foundation Professor of Translational Neuroscience at Michigan State University. His research interests are Alzheimer’s disease, aging and brain function. “We are privileged to welcome someone of Dr. Morgan’s…

TuesdayApr 16, 2024 3:41 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Receives Approval to Commence Human Pilot Study Evaluating GLP-1, DehydraTECH

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has received approval to begin a new human pilot study. The approval, which was granted by an independent third-party ethics review board, enables Lexaria to move forward with its plan to conduct a GLP-1 study investigating GLP-1 drugs and DehydraTECH(TM). According to the announcement, subject recruitment will begin immediately with the first dosing expected within the next month; the company plans to complete the study this summer. The study will be comprised of two study arms and will include up to nine healthy volunteers. The study is designed to…

TuesdayApr 16, 2024 1:33 pm

TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports on Promising Results from Study on INM-089 Treatment of Dry AMD

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on additional preclinical data for INM-089, a proprietary small molecule compound acting as a preferential signaling ligand of cannabinoid receptor 1 (“CB1”) and cannabinoid receptor 2 (“CB2”). The reported data continues to demonstrate positive pharmacological effects in the treatment of dry age-related macular degeneration (“AMD”). According to the announcement, in vivo preclinical studies in AMD disease models show that INM-089 delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement. Earlier results showed that INM-089 also preserved retinal function…

MondayApr 15, 2024 3:31 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Concentrating 2024 R&D Plans Mainly on GLP-1 Investigations

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced $3.6 million in gross proceeds from its registered direct offering. “Most notably, Lexaria intends to use the net proceeds from this offering for research and development (‘R&D’) studies and the associated patent and legal costs. It also intends to use the funds for general working capital purposes, important for its current focus on GLP-1 clinical studies for the 2024 calendar year… In 2023, Lexaria laid the groundwork for its GLP-1 clinical studies. The company achieved positive interim and final human pilot study results using a single…

MondayApr 15, 2024 1:37 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Represents Opportunity to Provide Solution for GBM Patients

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical-stage biopharmaceutical company advancing its lead drug candidate, Berubicin, along the pathway to potential regulatory approval and commercialization, recently appointed Amy Mahery to its board of directors. “A biotech commercialization leader, Ms. Mahery has built an illustrious career that spans more than 20 years. During this period, she has gained commercial expertise working with small and large companies in common and rare conditions, as well as across several therapeutic areas… Ms. Mahery lauded CNS Pharmaceuticals and its efforts to fill gaps in areas with high unmet medical needs, such as glioblastoma multiforme (‘GBM’) treatment, saying,…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

TinyGemsBreaks